文献速递临床试验与 GCP

维生素C、硫胺素与类固醇用于脓毒症(VICTAS)方案:一项前瞻性、多中心、双盲、自适应样本量、随机、安慰剂对照临床试验

The Vitamin C, Thiamine and Steroids in Sepsis (VICTAS) Protocol: a prospective, multi-center, double-blind, adaptive sample size, randomized, placebo-controlled, clinical trial.
PubMed 文献 · Trials · 2019-04-05

VICTAS是一项前瞻性、多中心、双盲、自适应样本量、随机、安慰剂对照试验,纳入因脓毒症导致呼吸或循环受损(或两者兼有)的患者,1:1随机接受静脉维生素C 1.5 g、硫胺素100 mg和氢化可的松50 mg每6小时一次或匹配安慰剂,直至完成16次给药或ICU出院(以先发生者为准)。主要结局为随机化后30天内无呼吸机和血管升压药支持的连续天数(VVFDs),关键次要结局为30天死亡率。样本量将通过中期分析自适应确定,并预设停止规则。

要点

  • VICTAS试验纳入因脓毒症导致呼吸或循环受损(或两者兼有)的患者。
  • 干预组每6小时静脉给予维生素C 1.5 g、硫胺素100 mg和氢化可的松50 mg,直至完成16次给药或ICU出院。
  • 主要结局为随机化后30天内无呼吸机和血管升压药支持的连续天数,关键次要结局为30天死亡率。

核心结论

  • VICTAS将检验维生素C、硫胺素和氢化可的松联合治疗对脓毒症所致呼吸或循环功能障碍(或两者兼有)患者的疗效。
  • 由于该联合治疗组分廉价易得且风险特征非常有利,若证实有效将对全球脓毒症管理产生直接影响。

研究设计与样本

  • VICTAS是一项前瞻性、多中心、双盲、自适应样本量、随机、安慰剂对照临床试验。
  • 纳入因脓毒症导致呼吸或循环受损(或两者兼有)的患者。
  • 患者按1:1随机接受静脉维生素C 1.5 g、硫胺素100 mg和氢化可的松50 mg每6小时一次或匹配安慰剂,直至完成16次给药或ICU出院(以先发生者为准)。
  • 随机分配至对照组的患者允许由治疗临床团队酌情接受开放标签的应激剂量类固醇。
  • 样本量将通过中期分析自适应确定,并预设停止规则,以便在存在大幅死亡率获益时早期识别,若未观察到早期大幅死亡率获益则重新聚焦于更敏感的VVFDs结局。

主要发现

  • 主要结局为随机化后30天内无呼吸机和血管升压药支持的连续天数(VVFDs)。
  • 关键次要结局为30天死亡率。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Sepsis accounts for 30% to 50% of all in-hospital deaths in the United States. Other than antibiotics and source control, management strategies are largely supportive with fluid resuscitation and respiratory, renal, and circulatory support. Intravenous vitamin C in conjunction with thiamine and hydrocortisone has recently been suggested to improve outcomes in patients with sepsis in a single-center before-and-after study. However, before this therapeutic strategy is adopted, a rigorous assessment of its efficacy is needed. METHODS: The Vitamin C, Thiamine and Steroids in Sepsis (VICTAS) trial is a prospective, multi-center, double-blind, adaptive sample size, randomized, placebo-controlled trial. It will enroll patients with sepsis causing respiratory or circulatory compromise or both. Patients will be randomly assigned (1:1) to receive intravenous vitamin C (1.5 g), thiamine (100 mg), and hydrocortisone (50 mg) every 6 h or matching placebos until a total of 16 administrations have been completed or intensive care unit discharge occurs (whichever is first). Patients randomly assigned to the comparator group are permitted to receive open-label stress-dose steroids at the discretion of the treating clinical team. The primary outcome is consecutive days free of ventilator and vasopressor support (VVFDs) in the 30 days following randomization. The key secondary outcome is mortality at 30 days. Sample size will be determined adaptively by using interim analyses with pre-stated stopping rules to allow the early recognition of a large mortality benefit if one exists and to refocus on the more sensitive outcome of VVFDs if an early large mortality benefit is not observed. DISCUSSION: VICTAS is a large, multi-center, double-blind, adaptive sample size, randomized, placebo-controlled trial that will test the efficacy of vitamin C, thiamine, and hydrocortisone as a combined therapy in patients with respiratory or circulatory dysfunction (or both) resulting from sepsis. Because the components of this therapy are inexpensive and readily available and have very favorable risk profiles, demonstrated efficacy would have immediate implications for the management of sepsis worldwide. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03509350 . First registered on April 26, 2018, and last verified on December 20, 2018. Protocol version: 1.4, January 9, 2019.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Hager DN, Hooper MH, Bernard GR, et al. The Vitamin C, Thiamine and Steroids in Sepsis (VICTAS) Protocol: a prospective, multi-center, double-blind, adaptive sample size, randomized, placebo-controlled, clinical trial. Trials. 2019. PMID: 30953543. doi:10.1186/s13063-019-3254-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。